CIS BIOPHARMA

CIS BIOPHARMA at Festival of Biologics

Basel, Switzerland, October 15, 2024 – CIS BIOPHARMA. a leading oncology-focused biotechnology firm, participated in the Festival of Biologics in Basel, Switzerland, reinforcing its position at the forefront of biologics innovation. The event is renowned as Europe’s premier biologics gathering where senior professionals from across the entire value chain convene. The three-day symposium offers a comprehensive exploration of cutting-edge advancements in antibodies, immunotherapeutics, and biosimilars. Key topics of particular relevance for CIS BIOPHARMA AG included AI driven drug development, novel indications for therapeutic antibodies and evolving clinical landscapes. 

Dominik Brücher, Chief Technology Officer, commented: «Our expertise in protein engineering and bioconjugation attracted the interest of various industry peers, fostering numerous high-value interactions . The knowledge acquired and networks established at the Festival of Biologics will catalyze our ongoing innovation efforts. We look forward to leveraging these insights and reconvening with colleagues at next year’s event.»

About CIS BIOPHARMA AG

CIS BIOPHARMA is a privately-owned, Basel-based oncology company developing next-generation immuno-conjugates to address aggressive forms of tumors. The company’s product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs,  that selectively target tumor cells. CIS BIOPHARMA is committed to helping cancer patients live longer and better lives.

 

We pioneer more effective cancer therapies to help cancer patients live longer and better lives.

Contact

CIS BIOPHARMA AG

Hauptstrasse 159
4416 Bubendorf
Switzerland

+41 61 935 53 33
hello@cisbiopharma.com

Copyright © 2024 CIS BIOPHARMA AG
Design by admaxx.ch